Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women

被引:78
作者
Hefler, LA
Tempfer, CB
Grimm, C
Lebrecht, A
Ulbrich, E
Heinze, G
Leodolter, S
Schneeberger, C
Mueller, MW
Muendlein, A
Koelbl, H
机构
[1] Med Univ Vienna, Dept Obstet & Gynecol, A-1090 Vienna, Austria
[2] Univ Mainz, Dept Obstet & Gynecol, Mainz, Germany
[3] Univ Halle Wittenberg, Sch Med, Dept Obstet & Gynecol, Halle Saale, Germany
[4] Univ Vienna, Dept Med Comp Sci, Vienna, Austria
[5] Univ Vienna, Inst Microbiol & Genet, Vienna, Austria
关键词
breast carcinoma; fibroadenoma; estrogen; gene; polymorphism;
D O I
10.1002/cncr.20361
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Genes encoding enzymes involved in estrogen metabolism are held to be candidate genes for associations with breast disease. In these candidate genes, no critical combination of single - nucleotide polymorphisms (SNPs) for assessing breast carcinoma risk has been reported to date. METHODS. in a large case-control study, the authors investigated 10 estrogen-metabolizing SNPs in 396 patients with breast carcinoma, 154 patients with fibroadenoma, and 1936 healthy control patients without breast carcinoma in their personal history. The following 10 SNPs were analyzed using sequencing-on-chip technology via a solid-phase polymerase chain reaction assay performed on oligonucleotide microarrays: catechol-O-methyltransferase Val158Met G-->A, 17-beta-hydroxysteroid dehydrogenase type I vIV A-->C, cytochrome P-450 (CYP) family 17 A2 allele T-->C, CYP1A1-1 MspI restriction fragment length polymorphism (RFLP) T-->C, CYP1A1-2 Ile462Val A-->G, CYP19-1 Trp39Arg T-->C, CYP19-2 Arg264Cys C-->T, CYP19-3 Cys1558Thr C-->T, steroid-5-alpha reductase type 2 Val89Leu G-->C, and vitamin D receptor BsmI RFLP. A total of 21,350 genotypes were evaluated. Associations and two-way interaction models were calculated using stepwise logistic regression. RESULTS. in a multiple model, CYP1A1-1 (P = 0.004) and CYP1A1-2 (P = 0.03) were found to be associated with significantly decreased and increased risks of breast carcinoma, respectively. When two-way interactions involving investigated SNPs were ascertained, no significant interactions among polymorphisms were noted. Comparison of patients with fibroadenoma with control patients revealed significantly increased and decreased risks of fibroadenoma when the mutant alleles of CYP17 (P = 0.02) and CYP1A1-1 (P = 0.04), respectively, were present. CONCLUSIONS. The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors ere. not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women. (C) 2004 American Cancer Society.
引用
收藏
页码:264 / 269
页数:6
相关论文
共 27 条
[1]  
AMBROSONE CB, 1995, CANCER RES, V55, P3483
[2]   Polymorphisms in CYP1A1 and smoking:: no association with breast cancer risk [J].
Basham, VM ;
Pharoah, PDP ;
Healey, CS ;
Luben, RN ;
Day, NE ;
Easton, DF ;
Ponder, BAJ ;
Dunning, AM .
CARCINOGENESIS, 2001, 22 (11) :1797-1800
[3]   Catechol-O-Methyltransferase (COMT) gene polymorphism and breast cancer risk in young women [J].
Bergman-Jungeström, M ;
Wingren, S .
BRITISH JOURNAL OF CANCER, 2001, 85 (06) :859-862
[4]  
de Amorim LMD, 2002, CANCER LETT, V181, P179
[5]  
DeMichele A, 2003, CANCER RES, V63, P8051
[6]   The role of ethnicity in cancer susceptibility gene polymorphisms:: the example of CYP1A1 [J].
Garte, S .
CARCINOGENESIS, 1998, 19 (08) :1329-1332
[7]   Meeting highlights:: Updated international expert consensus on the primary therapy of early breast cancer [J].
Goldhirsch, A ;
Wood, WC ;
Gelber, RD ;
Coates, AS ;
Thürlimann, B ;
Senn, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3357-3365
[8]  
Goode EL, 2002, CANCER RES, V62, P3052
[9]   Estrogen-metabolizing gene polymorphisms, but not estrogen receptor-α gene polymorphisms, are associated with the onset of menarche in healthy postmenopausal Japanese women [J].
Gorai, I ;
Tanaka, K ;
Inada, M ;
Morinaga, H ;
Uchiyama, Y ;
Kikuchi, R ;
Chaki, O ;
Hirahara, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (02) :799-803
[10]  
Haiman CA, 1999, CANCER RES, V59, P1015